Cassava Sciences (NASDAQ:SAVA) Raised to Hold at Zacks Investment Research

Last updated on Friday, July 23, 2021 | 2021 MarketBeat

Cassava Sciences (NASDAQ:SAVA) was upgraded by Zacks Investment Research from a "sell" rating to a "hold" rating in a report released on Friday, Zacks.com reports.

According to Zacks, "Cassava Sciences Inc. is focused on the early detection and treatment of neurodegenerative diseases, such as Alzheimer's. Cassava Sciences Inc., formerly known as Pain Therapeutics Inc., is based in Austin, United States. "

Several other brokerages have also recently issued reports on SAVA. HC Wainwright raised their target price on shares of Cassava Sciences from $97.00 to $124.00 and gave the stock a "buy" rating in a report on Tuesday. Cantor Fitzgerald lowered Cassava Sciences from an "overweight" rating to a "neutral" rating and set a $100.00 price target for the company. in a research note on Thursday, July 15th. Finally, B. Riley raised their price target on Cassava Sciences from $78.00 to $111.00 and gave the stock a "buy" rating in a research note on Wednesday, June 23rd. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company currently has an average rating of "Buy" and an average target price of $79.60.

Shares of Cassava Sciences stock opened at $126.61 on Friday. Cassava Sciences has a 52-week low of $2.78 and a 52-week high of $130.47. The company has a market capitalization of $5.07 billion, a PE ratio of -436.57 and a beta of 1.09. The business has a 50 day moving average price of $75.29.

Cassava Sciences (NASDAQ:SAVA) last issued its earnings results on Tuesday, April 20th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.01. Sell-side analysts predict that Cassava Sciences will post -0.76 earnings per share for the current year.

A number of institutional investors have recently made changes to their positions in SAVA. Nuveen Asset Management LLC lifted its position in Cassava Sciences by 569.1% during the fourth quarter. Nuveen Asset Management LLC now owns 611,863 shares of the company's stock valued at $2,032,000 after buying an additional 520,414 shares during the period. BlackRock Inc. increased its holdings in shares of Cassava Sciences by 22.0% during the first quarter. BlackRock Inc. now owns 2,404,922 shares of the company's stock valued at $108,102,000 after acquiring an additional 434,153 shares in the last quarter. Bleichroeder LP increased its holdings in shares of Cassava Sciences by 75.9% during the first quarter. Bleichroeder LP now owns 500,000 shares of the company's stock valued at $22,475,000 after acquiring an additional 215,686 shares in the last quarter. Morgan Stanley increased its holdings in shares of Cassava Sciences by 337.0% during the first quarter. Morgan Stanley now owns 223,362 shares of the company's stock valued at $10,040,000 after acquiring an additional 172,250 shares in the last quarter. Finally, Wells Fargo & Company MN increased its holdings in shares of Cassava Sciences by 187.3% during the fourth quarter. Wells Fargo & Company MN now owns 164,571 shares of the company's stock valued at $1,122,000 after acquiring an additional 107,286 shares in the last quarter. 26.57% of the stock is owned by institutional investors and hedge funds.

About Cassava Sciences

Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.

Featured Story: Why is the price-sales ratio important?

Get a free copy of the Zacks research report on Cassava Sciences (SAVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Cassava Sciences (NASDAQ:SAVA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $1,000 in Cassava Sciences right now?

Before you consider Cassava Sciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cassava Sciences wasn't on the list.

While Cassava Sciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here

 


MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.